Both in Pharmaceuticals
TransCode Therapeutics vs NextCure
Over the past year RNAZ returned −85.1% and NXTC returned −50.7%; their daily moves had a correlation of 0.09.
RNAZ −85.1% NXTC −50.7%Growth of $1, one year, split-adjusted
| Metric | RNAZ | NXTC |
|---|---|---|
| Price | $1.57 | $5.91 |
| Market cap | $26.6M | $27.1M |
| Today | −3.68% | +3.78% |
| 1 month | −10.8% | +17.0% |
| 6 months | −80.0% | −36.6% |
| Year to date | −77.0% | −58.4% |
| 1 year | — | −53.1% |
| Revenue growth (YoY) | — | — |
| Gross margin | — | — |
| Net margin | — | — |
| P/E (TTM) | — | — |
| Price / sales | — | — |
| Net cash | $7.7M | $20.1M |
| Dividend yield | — | — |
| Volatility (60d) | 75.6% | 111.0% |
| Short % of float | 8.1% | 8.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).